1. Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer
- Author
-
Minjung Jung, Sung Ui Jung, Jin Hyuk Choi, and Chang Wan Jeon
- Subjects
Oncology ,medicine.medical_specialty ,RCB classification ,Pyridines ,letrozole ,Breast surgery ,medicine.medical_treatment ,Sentinel lymph node ,Antineoplastic Agents ,Breast Neoplasms ,neo-systemic therapy ,Palbociclib ,Mastectomy, Segmental ,Piperazines ,CDK4/6 inhibitor ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Internal medicine ,medicine ,Humans ,Clinical Case Report ,030212 general & internal medicine ,skin and connective tissue diseases ,Protein Kinase Inhibitors ,Lymph node ,business.industry ,Letrozole ,Carcinoma, Ductal, Breast ,General Medicine ,Middle Aged ,medicine.disease ,Neoadjuvant Therapy ,medicine.anatomical_structure ,Docetaxel ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Female ,business ,Research Article ,medicine.drug - Abstract
Rationale. Neo-adjuvant systemic therapy includes endocrine therapy and chemotherapy, which is widely used. Luminal breast cancer is resistant to chemotherapy and is more likely to not respond to chemotherapy before surgery. Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor. Palbociclib with letrozole combination therapy was an effective chemotherapy in metastatic luminal type breast cancer and had fewer side effects; however, the benefit of palbociclib in neoadjuvant systemic therapy is unclear. Patient concerns A 50-year-old female patient visited our hospital with palpable lump in the right breast. The lymph nodes fixed in the ipsilateral axilla. Diagnosis The patient was diagnosed with invasive ductal carcinoma of the right breast; the nuclear grade was moderate. The ipsilateral fixed lymph node was diagnosed as metastasis. The breast cancer subtype was luminal A type and was positive for estrogen receptor and progesterone receptor, and negative for HER2/neu and Ki-67 marker index
- Published
- 2021
- Full Text
- View/download PDF